Pfizer in talks to merge off-patent drugs business with Mylan


FILE PHOTO: The logo of U.S. pharmaceutical corporation Pfizer Inc. is seen at a branch in Zurich, Switzerland October 2, 2018. REUTERS/Arnd Wiegmann

(Reuters) – Pfizer Inc (PFE.N) is in talks to merge its off-patent drugs business with Mylan NV (MYL.O) in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Pfizer and Mylan did not immediately respond to requests for comment.

Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter

Products You May Like

Articles You May Like

Tropical Storm Humberto lashes Bahamas, seen becoming hurricane
Biden’s bid to attract Rust Belt workers faces troubles in his own backyard
PM Johnson could recall parliament if suspension ruled unlawful
Explainer: U.S. enacts sweeping new asylum bar following Supreme Court decision
Cars front man Ric Ocasek died while recovering from surgery: family

Leave a Reply

Your email address will not be published. Required fields are marked *